Osteoprotegerin as a Marker of Cardiovascular Events in Patients with Chronic Kidney Disease | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 19, Volume 101, Issue 1, October 2025, Pages 4714-4720 PDF (488.3 K) | ||
| DOI: 10.21608/ejhm.2025.456583 | ||
| Abstract | ||
| Background: Cardiovascular disease (CVD) represents the primary cause of death among individuals with End-stage renal disease (ESRD). Osteoprotegerin (OPG), a key modulator of bone metabolism that inhibits osteoclast differentiation and activation, has been implicated in vascular calcification. Elevated serum OPG concentrations have been accompanied with aortic calcification and elevated mortality risk in ESRD individuals. Objectives: This study aimed to evaluate the utility of serum OPG as an indicator for CVD in ESRD patients. Methods: In this cross-sectional study, 86 ESRD participants (44 males, 42 females) underwent comprehensive clinical evaluation, laboratory tests encompassing complete blood count (CBC), serum creatinine, liver enzymes, and imaging (Doppler ultrasound to measure carotid IMT and Echocardiography). Serum OPG concentrations were assayed. Results: Serum OPG was liable to be a predictor of left ventricular hypertrophy (LVH) and increased LV cavity size. An OPG cutoff value >14 ng/mL predicted LVH with 62.5% sensitivity and 100% specificity. Similarly, a cutoff >12 ng/mL predicted increased LV cavity size with 100% sensitivity and 62.5% specificity. Conclusion: Elevated serum OPG concentrations were related to elevated cardiovascular risk in ESRD participants and may serve as a valuable biomarker for early recognition of LV structural abnormalities. Large multicentric studies are warranted to validate this conclusion. | ||
| Keywords | ||
| Osteoprotegerin; Marker; Cardiovascular; Chronic Kidney Disease | ||
|
Statistics Article View: 137 PDF Download: 57 |
||
